Project Grant HT94252510150
Award Date
5/1/25
Completion Date
4/30/29
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $780,357.00 to The Cleveland Clinic Foundation to investigate the novel nuclear localization of the complement regulator CD55 and its impact on disrupting ovarian cancer progression. The 4-year project, starting on May 1, 2025 and concluding on April 30, 2029, aims to advance scientific understanding and develop innovative approaches for addressing this...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,159,998.00 to The Cleveland Clinic Foundation, a non-profit academic medical center, to fund a research project titled "THERAPEUTIC IMMUNOSTIMULATORY MICROBES FOR TREATMENT OF OVARIAN CANCER". The award, which runs from September 1, 2024 to August 31, 2028, will support the Foundation's innovative biomedical research into developing...
This federal Project Grant award, with an ID of HT94252510141, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, totaling $240,000.00, was awarded to The Cleveland Clinic Foundation, a prominent non-profit academic medical center, to explore the causality and mechanisms of androgen receptor (AR) ecdysone in the progression of malignant prostate cancer. The award has a performance period from March 15, 2025 to March 14,...
This Project Grant award of $471,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The funding supports research by The Cleveland Clinic Foundation to develop next-generation prostate cancer therapeutics by exploiting the allosteric regulation of the androgen receptor. The award period is from September 1, 2023 to August 31, 2025. As a prime recipient of federal grants, The Cleveland Clinic Foundation has a history of...
The Defense Health Agency awarded The Cleveland Clinic Foundation, a non-profit academic medical center, a $893,768 Project Grant under the Military Medical Research and Development (CFDA 12.420) program. The two-year grant, effective from September 1, 2023 to August 31, 2025, supports the development of multimodal AI-based solutions to enhance renal cancer patient care. As a leader in medical research, education, and healthcare delivery, The Cleveland Clinic Foundation will leverage its...
The Defense Health Agency awarded a $640,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation, a non-profit academic medical center, to conduct research focused on "Evolutionary Experimentation Highlights Novel Therapeutic Vulnerabilities in Endometrial Cancer." The award duration is from September 1, 2024 to August 31, 2026. The Cleveland Clinic Foundation, which has extensive experience as both a prime...
This $1,280,000 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) funds research conducted by The Cleveland Clinic Foundation to investigate how the NF-I/A transcription factor regulates an HIF-independent fatty acid metabolism program in kidney cancer. The award, with a performance period from September 1, 2024 to August 31, 2028, supports the Cleveland Clinic Foundation's research to develop innovative medical solutions for...
The Department of Defense's Defense Health Agency awarded The Cleveland Clinic Foundation a $383,740 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 30, 2024, supports the research and development of a "Novel Graft-Localized Drug Delivery Platform for Attenuating Innate Inflammation and Optimizing Immunosuppression in Vascularized Composite Allotransplantation." This project aims to develop innovative medical...
This Project Grant award in the amount of $559,874 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation. The award will fund research targeting genomic drivers of Hurthle cell thyroid cancer through the use of mTOR and eIF2 inhibition. The performance period for this grant is from September 30, 2024 to September 29, 2026. As a leading academic medical center and research institution, The Cleveland...
This Project Grant award, valued at $1,200,000.00, was provided by the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation. The grant supports research to disrupt the CX26-FAK-NANOG complex in order to attenuate cancer stem cell self-renewal and progression of triple-negative breast cancer. The 3-year project, running from May 2025 to April 2028, aims to develop innovative therapeutic strategies to address this challenging...